Cargando…

Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial

BACKGROUND: Anti-leishmanial drug regimens that include a single dose AmBisome® could be suitable for eastern African patients with symptomatic visceral leishmaniasis (VL) but the appropriate single dose is unknown. METHODOLOGY: A multi-centre, open-label, non-inferiority, randomized controlled tria...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khalil, Eltahir A. G., Weldegebreal, Teklu, Younis, Brima M., Omollo, Raymond, Musa, Ahmed M., Hailu, Workagegnehu, Abuzaid, Abuzaid A., Dorlo, Thomas P. C., Hurissa, Zewdu, Yifru, Sisay, Haleke, William, Smith, Peter G., Ellis, Sally, Balasegaram, Manica, EL-Hassan, Ahmed M., Schoone, Gerard J., Wasunna, Monique, Kimutai, Robert, Edwards, Tansy, Hailu, Asrat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894173/ https://www.ncbi.nlm.nih.gov/pubmed/24454970 http://dx.doi.org/10.1371/journal.pntd.0002613

Ejemplares similares

Single-dose liposomal amphotericin B (AmBisome(®)) for the treatment of Visceral Leishmaniasis in East Africa: study protocol for a randomized controlled trial
por: Edwards, Tansy, et al.
Publicado: (2011)

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial
por: Wasunna, Monique, et al.
Publicado: (2016)

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia
por: Diro, Ermias, et al.
Publicado: (2019)

Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial
por: Musa, Ahmed, et al.
Publicado: (2012)

Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
por: Omollo, Raymond, et al.
Publicado: (2011)

Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study
por: Musa, Ahmed M., et al.
Publicado: (2010)

Polymorphism in the HASPB Repeat Region of East African Leishmania donovani Strains
por: Zackay, Arie, et al.
Publicado: (2013)

Inference of Population Structure of Leishmania donovani Strains Isolated from Different Ethiopian Visceral Leishmaniasis Endemic Areas
por: Gelanew, Tesfaye, et al.
Publicado: (2010)

Parasitic Loads in Tissues of Mice Infected with Trypanosoma cruzi and Treated with AmBisome
por: Cencig, Sabrina, et al.
Publicado: (2011)

Immediate hypersensitivity reaction following liposomal amphotericin-B (AmBisome) infusion
por: Nath, Proggananda, et al.
Publicado: (2014)

Correction: Arginase Activity in the Blood of Patients with Visceral Leishmaniasis and HIV Infection
por: Takele, Yegnasew, et al.
Publicado: (2013)

Arginase Activity in the Blood of Patients with Visceral Leishmaniasis and HIV Infection
por: Takele, Yegnasew, et al.
Publicado: (2013)

Hypokalaemia-Induced Rhabdomyolysis after Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL) with High-Dose AmBisome in Bangladesh—A Case Report
por: Marking, Ulrika, et al.
Publicado: (2014)

Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial
por: Hailu, Asrat, et al.
Publicado: (2010)

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh
por: Rahman, Ridwanur, et al.
Publicado: (2017)

Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2018)

AmBisome Monotherapy and Combination AmBisome–Miltefosine Therapy for the Treatment of Visceral Leishmaniasis in Patients Coinfected With Human Immunodeficiency Virus in India: A Randomized Open-Label, Parallel-Arm, Phase 3 Trial( )
por: Burza, Sakib, et al.
Publicado: (2022)

The Viscoelastic Properties of the Fungal Cell Wall Allow Traffic of AmBisome as Intact Liposome Vesicles
por: Walker, Louise, et al.
Publicado: (2018)

Cytotoxicity of Amphotericin B and AmBisome: In Silico and In Vivo Evaluation Employing the Chick Embryo Model
por: Khosravi, Ahmad, et al.
Publicado: (2022)

The Economic Burden of Visceral Leishmaniasis in Sudan: An Assessment of Provider and Household Costs
por: Meheus, Filip, et al.
Publicado: (2013)

AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial
por: Lawrence, David S., et al.
Publicado: (2018)

AMBIsome Therapy Induction OptimisatioN (AMBITION): High dose AmBisome for cryptococcal meningitis induction therapy in sub-Saharan Africa: economic evaluation protocol for a randomised controlled trial-based equivalence study
por: Ponatshego, Ponego Lloyd, et al.
Publicado: (2019)

Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial
por: Lawrence, David S., et al.
Publicado: (2019)

A Comparison of AmBisome(®) to Amphotericin B for Treatment of Systemic Candidiasis in Very Low Birth Weight Infants
por: Jeon, Ga Won, et al.
Publicado: (2007)

Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome(®) and AmBisome(®) in murine cutaneous leishmaniasis
por: Wijnant, Gert-Jan, et al.
Publicado: (2018)

Tissue-specific transcriptomic changes associated with AmBisome® treatment of BALB/c mice with experimental visceral leishmaniasis
por: Forrester, Sarah, et al.
Publicado: (2019)

Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients
por: Verrest, Luka, et al.
Publicado: (2021)

Effectiveness and Safety of Short Course Liposomal Amphotericin B (AmBisome) as First Line Treatment for Visceral Leishmaniasis in Bangladesh
por: Lucero, Emiliano, et al.
Publicado: (2015)

AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial
por: Molefi, Mooketsi, et al.
Publicado: (2015)

Visceral Leishmaniasis and HIV Co-infection in Bihar, India: Long-term Effectiveness and Treatment Outcomes with Liposomal Amphotericin B (AmBisome)
por: Burza, Sakib, et al.
Publicado: (2014)

The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study
por: Abongomera, Charles, et al.
Publicado: (2018)

AmBisome Induced Avascular Necrosis of the Alae of the Nose of a very young girl suffering from Kala‐azar – a Case Report
por: Maruf, Shomik, et al.
Publicado: (2016)

Blood Parasite Load as an Early Marker to Predict Treatment Response in Visceral Leishmaniasis in Eastern Africa
por: Verrest, Luka, et al.
Publicado: (2021)

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study
por: Dorlo, Thomas P C, et al.
Publicado: (2017)

The Leishmaniasis East Africa Platform (LEAP): strengthening clinical trial capacity in resource-limited countries to deliver new treatments for visceral leishmaniasis
por: Wasunna, Monique, et al.
Publicado: (2016)

Arginase Activity - A Marker of Disease Status in Patients with Visceral Leishmaniasis in Ethiopia
por: Abebe, Tamrat, et al.
Publicado: (2013)

Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme
por: Kimutai, Robert, et al.
Publicado: (2017)

Low-Dose Chest CT Protocols for Imaging COVID-19 Pneumonia: Technique Parameters and Radiation Dose
por: Suliman, Ibrahim I., et al.
Publicado: (2023)

Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study
por: Kip, Anke E, et al.
Publicado: (2021)

Innovative Approaches to Clinical Data Management in Resource Limited Settings Using Open-Source Technologies
por: Omollo, Raymond, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_v220lcntf3ca1e5aqq1lki71vp